Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical vs Oral Sirolimus for Superficial Vascular Anomalies
NCT04921722Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Oct 2021
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sirolimus in kaposiform hemangioendothelioma (KHE), tufted angioma (TA), vascular anomaly, superficial lymphatic malformation (LM), sponsored by Children's Hospital of Fudan University. Started Oct 2021; status: recruiting.
02
Drugs
sirolimus
03
Conditions
kaposiform hemangioendothelioma (KHE)tufted angioma (TA)vascular anomalysuperficial lymphatic malformation (LM)
Beyond the preview
Go deeper on NCT04921722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04921722.